Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
December 21, 2021 5:08 PM 2 min read

COVID Testing Kit Makers Respond To Biden's Call For 500 Million Free At-Home Tests

by Michael Cohen Benzinga Editor
Follow

ArticleFeaturedTickersList12345!!!

President Joe Biden announced his administration’s strategy for curbing the spread of the omicron variant of the coronavirus includes ordering 500 million at-home tests to ship free to Americans.

What Happened: During a Tuesday afternoon speech, Biden said omicron will cause breakthrough infections among vaccinated Americans in “potentially in large numbers,” although the cases are unlikely to be severe, he added.

The president announced 500 million free at-home tests will be in addition to getting at-home tests reimbursed, which will go into effect on Jan. 15.

Related Link: As COVID-19 Testing Takes Center Stage Again, GENETWORx Labs Announces Testing Capacity and Availability to Help Meet Individual and Corporate Testing Demand

Douglas Bryant, president and CEO of Quidel Corporation (NASDAQ:QDEL), a provider of rapid diagnostic testing solutions, said his company is "anticipating continued strong demand approaching the Holidays based on the recent rise in infection rates and our discussions with employers, institutions and the federal government."

Quidel is producing as many testing kits as possible, Bryant told Benzinga.

"Our people are working tirelessly to increase our manufacturing capacity to a run-rate of 70 million tests per month by the end of the year," he said. "Part of that production is dedicated to fulfilling a 12-month federal government contract estimated at approximately 100 million QuickVue® At-Home OTC COVID-19 Tests."

An Abbott Laboratories (NYSE:ABT) spokesperson responded to Biden’s announcement, saying, "I can tell you that since the onset of the pandemic, no company has done more to make testing available to Americans than Abbott."

"In January, we'll be making 70 million BinaxNOW rapid tests and can scale significantly further in the months ahead," the Abbott spokesperson added.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
GovernmentNewsHealth CareTop StoriesExclusivesGeneralCovid-19Joe BidenOmicron
ABT Logo
ABTAbbott Laboratories
$109.09-0.29%
Overview
QDEL Logo
QDELQuidelOrtho Corp
$27.65-%
ABT Logo
ABTAbbott Laboratories
$109.09-0.29%
Overview
QDEL Logo
QDELQuidelOrtho Corp
$27.65-%
Comments
Loading...